search
Back to results

Beta-Blocker Continuation Versus Interruption in Heart Failure Worsening (BConvinced)

Primary Purpose

Heart Failure, Congestive

Status
Completed
Phase
Phase 4
Locations
France
Study Type
Interventional
Intervention
beta-blocker treatment
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Heart Failure, Congestive focused on measuring Heart Failure, Congestive, beta-Adrenergic Blockers

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients with heart failure treated with beta-blocker; hospitalisation for heart failure worsening with pulmonary oedema. Left ventricular ejection fraction less than 40% Exclusion Criteria: Indication of intravenous positive inotropic treatment Indication to withdraw beta-blocker treatment

Sites / Locations

  • Hôpital Victor Dupuy
  • Les Etablissements Hospitaliers du Bessin
  • Hôpital Ambroise Paré
  • Centre Hospitalier Universitaire de Caen
  • Hôpital Fontenoy de Chartres
  • Centre Hospitalier de Cholet
  • Hôpital Antoine Béclère
  • Hôpital Beaujon
  • Hôpital de Corbeil
  • Hôpital Henri Mondor
  • Hôpital du Bocage
  • Hôpital A. Michallon
  • Centre Hospitalier de Versailles
  • Hôpital Saint-Philibert
  • Hôpital Saint-Joseph Saint-Luc
  • Hôpital de la Timone
  • Hôpital Arnaud de Villeneuve
  • Hôpital René Laënnec
  • Hôpital Pasteur
  • Hôpital des Armées du Val de Grâce
  • Hôpital Lariboisière
  • Groupe Hospitalier Pitié-Salpêtrière
  • Hôpital Européen Georges Pompidou
  • Hôpital Saint-Michel
  • Centre Hospitalier Universitaire La Milétrie
  • Centre Hospitalier Regional Dubos
  • Centre Hospitalier Universitaire Potcaillou
  • Hôpital Charles Nicolle
  • Centre Hospitalier Universitaire Hautepierre
  • Hôpital de Rangueil
  • Hôpital Trousseau
  • Hôpital de Brabois

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

1

Arm Description

bbloquant treatment

Outcomes

Primary Outcome Measures

Clinical status (questionnaire): the percentage (%) of patients with clinical improvement is the primary endpoint criterion.

Secondary Outcome Measures

Clinical status (evaluation by investigator and autoevaluation by patient)
BNP change
Mortality, hospital admission, % of patients with beta-blocker treatment

Full Information

First Posted
September 9, 2005
Last Updated
May 22, 2009
Sponsor
Assistance Publique - Hôpitaux de Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT00162565
Brief Title
Beta-Blocker Continuation Versus Interruption in Heart Failure Worsening
Acronym
BConvinced
Official Title
Beta-Blocker Continuation Versus Interruption in Patients With Congestive Heart Failure Hospitalized for Heart Failure Worsening (B-CONVINCED)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2005
Overall Recruitment Status
Completed
Study Start Date
November 2004 (undefined)
Primary Completion Date
February 2009 (Actual)
Study Completion Date
February 2009 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Assistance Publique - Hôpitaux de Paris

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The objective of the B-Convinced study is to demonstrate the non-inferiority of beta-blocker continuation compared to its interruption in patients with congestive heart failure who are treated by a beta-blocker and present with an episode of heart failure worsening with pulmonary oedema requiring hospital admission. 162 patients will be randomized in cardiology centers in France. Clinical status (primary endpoint) will be evaluated with a standardized questionnaire 3 days after hospital admission.
Detailed Description
Therapeutic strategy of beta-blocker treatment during an episode of heart failure worsening remains unclear. The objective of the B-Convinced study is to demonstrate that continuation of beta-blocker treatment in case of hospitalisation for heart failure worsening is as safe as the interruption of such treatment. Hypothesis: The proportion of patients clinically improving within 3 days is not inferior when beta-blocker treatment is maintained compared to beta-blocker interruption in case of hospitalisation for heart failure worsening with pulmonary oedema. Design: Open, randomized non-inferiority trial on two parallel groups of patients. Randomization performed centrally with a vocal server. Tested Hypothesis: 90% of success in the interruption group, power of 80%, non-inferiority limit of 15% (relative reduction). 162 patients are required with such a hypothesis. Primary Endpoint: Clinical improvement within 3 days of hospital admission evaluated by the investigator by a standardized questionnaire. Secondary Endpoints: Clinical improvement at day 8 or at hospital discharge, morbidity-mortality at 4 months. 34 participating centres in France.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure, Congestive
Keywords
Heart Failure, Congestive, beta-Adrenergic Blockers

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
180 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
bbloquant treatment
Intervention Type
Drug
Intervention Name(s)
beta-blocker treatment
Intervention Description
beta-blocker treatment
Primary Outcome Measure Information:
Title
Clinical status (questionnaire): the percentage (%) of patients with clinical improvement is the primary endpoint criterion.
Time Frame
at day 3 of hospital admission
Secondary Outcome Measure Information:
Title
Clinical status (evaluation by investigator and autoevaluation by patient)
Time Frame
at day 8 after hospital admission
Title
BNP change
Time Frame
between admission, day 3 and day 8
Title
Mortality, hospital admission, % of patients with beta-blocker treatment
Time Frame
at 3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with heart failure treated with beta-blocker; hospitalisation for heart failure worsening with pulmonary oedema. Left ventricular ejection fraction less than 40% Exclusion Criteria: Indication of intravenous positive inotropic treatment Indication to withdraw beta-blocker treatment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Philippe P Lechat, MD, PhD
Organizational Affiliation
Hopital Pitie-Salpetriere, Paris, France
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Guillaume Jondeau, MD, PhD
Organizational Affiliation
Hopital Ambroise-Pare, Boulogne, France
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hôpital Victor Dupuy
City
Argenteuil
ZIP/Postal Code
95107
Country
France
Facility Name
Les Etablissements Hospitaliers du Bessin
City
Bayeux
ZIP/Postal Code
14401
Country
France
Facility Name
Hôpital Ambroise Paré
City
Boulogne-Billancourt
ZIP/Postal Code
92100
Country
France
Facility Name
Centre Hospitalier Universitaire de Caen
City
Caen
ZIP/Postal Code
14033
Country
France
Facility Name
Hôpital Fontenoy de Chartres
City
Chartres
ZIP/Postal Code
28018
Country
France
Facility Name
Centre Hospitalier de Cholet
City
Cholet
ZIP/Postal Code
49325
Country
France
Facility Name
Hôpital Antoine Béclère
City
Clamart
ZIP/Postal Code
92141
Country
France
Facility Name
Hôpital Beaujon
City
Clichy
ZIP/Postal Code
92118
Country
France
Facility Name
Hôpital de Corbeil
City
Corbeil
ZIP/Postal Code
91106
Country
France
Facility Name
Hôpital Henri Mondor
City
Créteil
ZIP/Postal Code
94000
Country
France
Facility Name
Hôpital du Bocage
City
Dijon
ZIP/Postal Code
21000
Country
France
Facility Name
Hôpital A. Michallon
City
Grenoble
ZIP/Postal Code
38009
Country
France
Facility Name
Centre Hospitalier de Versailles
City
Le Chesnay
ZIP/Postal Code
78157
Country
France
Facility Name
Hôpital Saint-Philibert
City
Lomme
ZIP/Postal Code
59462
Country
France
Facility Name
Hôpital Saint-Joseph Saint-Luc
City
Lyon
ZIP/Postal Code
69007
Country
France
Facility Name
Hôpital de la Timone
City
Marseille
ZIP/Postal Code
13005
Country
France
Facility Name
Hôpital Arnaud de Villeneuve
City
Montpellier
ZIP/Postal Code
34295
Country
France
Facility Name
Hôpital René Laënnec
City
Nantes
ZIP/Postal Code
44093
Country
France
Facility Name
Hôpital Pasteur
City
Nice
ZIP/Postal Code
06002
Country
France
Facility Name
Hôpital des Armées du Val de Grâce
City
Paris
ZIP/Postal Code
75005
Country
France
Facility Name
Hôpital Lariboisière
City
Paris
ZIP/Postal Code
75010
Country
France
Facility Name
Groupe Hospitalier Pitié-Salpêtrière
City
Paris
ZIP/Postal Code
75013
Country
France
Facility Name
Hôpital Européen Georges Pompidou
City
Paris
ZIP/Postal Code
75015
Country
France
Facility Name
Hôpital Saint-Michel
City
Paris
ZIP/Postal Code
75015
Country
France
Facility Name
Centre Hospitalier Universitaire La Milétrie
City
Poitiers
ZIP/Postal Code
86021
Country
France
Facility Name
Centre Hospitalier Regional Dubos
City
Pontoise
ZIP/Postal Code
95301
Country
France
Facility Name
Centre Hospitalier Universitaire Potcaillou
City
Rennes
ZIP/Postal Code
35033
Country
France
Facility Name
Hôpital Charles Nicolle
City
Rouen
ZIP/Postal Code
76031
Country
France
Facility Name
Centre Hospitalier Universitaire Hautepierre
City
Strasbourg
ZIP/Postal Code
67098
Country
France
Facility Name
Hôpital de Rangueil
City
Toulouse
ZIP/Postal Code
31403
Country
France
Facility Name
Hôpital Trousseau
City
Tours
ZIP/Postal Code
37044
Country
France
Facility Name
Hôpital de Brabois
City
Vandoeuvre-les-Nancy
ZIP/Postal Code
54511
Country
France

12. IPD Sharing Statement

Learn more about this trial

Beta-Blocker Continuation Versus Interruption in Heart Failure Worsening

We'll reach out to this number within 24 hrs